Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Cell Metabolism|December 3, 2014
Reducing macrophage proteoglycan sulfation increases atherosclerosis and obesity through enhanced type I interferon signalingPhilip L S M Gordts, Erin M Foley, Roger Lawrence, et al.
Molecular Genetics and Metabolism|June 22, 2014
Intra-articular enzyme replacement therapy with rhIDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type IRaymond Y Wang, Afshin Aminian, Michael F McEntee, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 15, 2015
A common sugar-nucleotide-mediated mechanism of inhibition of (glycosamino)glycan biosynthesis, as evidenced by 6F-GalNAc (Ac3)Xander M van Wijk, Roger Lawrence, Victor L Thijssen, et al.
Scientific Reports|November 24, 2020
Central nervous system pathology in preclinical MPS IIIB dogs reveals progressive changes in clinically relevant brain regionsMartin T Egeland, Marta M Tarczyluk-Wells, Melissa M Asmar, et al.
Journal of Neuropathology and Experimental Neurology|March 29, 2025
Multi-omic analysis of meningeal cerebral amyloid angiopathy reveals enrichment of unsubstituted glucosamine and extracellular proteinsJoshua E Mayfield, Alexander J Rajic, Patricia Aguilar-Calvo, et al.
ACS Chemical Biology|August 27, 2013
Interfering with UDP-GlcNAc metabolism and heparan sulfate expression using a sugar analogue reduces angiogenesisXander M van Wijk, Victor L Thijssen, Roger Lawrence, et al.
Plos One|January 3, 2025
Intracerebroventricular administration of a modified hexosaminidase ameliorates late-stage neurodegeneration in a GM2 mouse modelManuel E Lopez, Daniel Wendt, Roger Lawrence, et al.
The Journal of Biological Chemistry|September 5, 2019
Intracerebroventricular enzyme replacement therapy with β-galactosidase reverses brain pathologies due to GM1 gangliosidosis in miceJoseph C Chen, Amanda R Luu, Nathan Wise, et al.
Molecular Therapy. Methods & Clinical Development|July 1, 2017
Clearance of Heparan Sulfate and Attenuation of CNS Pathology by Intracerebroventricular BMN 250 in Sanfilippo Type B MiceMika Aoyagi-Scharber, Danielle Crippen-Harmon, Roger Lawrence, et al.
Drug Delivery and Translational Research|January 17, 2020
Translational studies of intravenous and intracerebroventricular routes of administration for CNS cellular biodistribution for BMN 250, an enzyme replacement therapy for the treatment of Sanfilippo type BAnita Grover, Danielle Crippen-Harmon, Lacey Nave, et al.
Pageof 6